Cato Research Ltd., VistaGen deal

VistaGen partnered with CRO Cato Research and its Cato Ventures venture capital affiliate to indentify and develop small molecule drugs candidates that were discontinued in preclinical development by pharmaceuticals companies due to heart or liver toxicity, but showed positive efficacy data. VistaGen will have exclusive first rights to information on drug candidates identified by Cato, which will then have first rights to provide CRO service to VistaGen if the candidate is selected for development. ...